SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (877)11/23/1997 11:11:00 AM
From: Tunica Albuginea  Read Replies (1) | Respond to of 7041
 
BigKNY3, Re;"TA: Drafts of proposed papers for unapproved products are prepared only upon completion of the Phase III clinical studies. These drafts are then submitted to a publication for peer review which can take anywhere from 3 to 18 months. Accordingly, it is not surprising that most pharmaceuticals that have not been approved by the FDA do not have published papers in medical journals."

I am aware of the.
The point here is that neither Zona, nor the FDA or Dauntless for that matter can change the basic pharmacological behavior of phentolamine.The drug is well studied for 50 years for goodness sake.
As comrade Asensio said, this is generically available.

Nobody has a patent to it .

Any body can stick it in an M&M and sell it.

TA



To: BigKNY3 who wrote (877)11/23/1997 10:07:00 PM
From: Anaxagoras  Read Replies (1) | Respond to of 7041
 
I would just like to add to BigKNY3's insightful comments regarding the release of peer reviewed publications and respond to other concerns on this thread over the lack of data that, as a first step, Zonagen is planning to put together and release a white paper in the near term (as soon as, perhaps, within a number of weeks, as per the conference call).

Anaxagoras


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News